Kestra Medical Technologies (NASDAQ:KMTS) Insider Alfred Ford, Jr. Sells 6,275 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 6,275 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.09, for a total transaction of $151,164.75. Following the sale, the insider directly owned 99,564 shares in the company, valued at approximately $2,398,496.76. This trade represents a 5.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Up 0.8%

Shares of KMTS stock opened at $25.27 on Friday. Kestra Medical Technologies, Ltd. has a 1 year low of $14.10 and a 1 year high of $30.00. The company’s fifty day simple moving average is $22.86 and its two-hundred day simple moving average is $22.54. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -10.44 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The firm had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. As a group, analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Institutional Trading of Kestra Medical Technologies

Large investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC bought a new stake in shares of Kestra Medical Technologies during the 4th quarter valued at $31,000. Russell Investments Group Ltd. grew its holdings in Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after acquiring an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Kestra Medical Technologies in the fourth quarter worth about $72,000. Finally, Brown Brothers Harriman & Co. increased its stake in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have recently issued reports on KMTS. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. The Goldman Sachs Group dropped their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. Finally, BTIG Research upped their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kestra Medical Technologies currently has a consensus rating of “Hold” and a consensus target price of $27.83.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.